Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-23
DOI
10.1038/s41375-020-0876-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
- (2020) Zunyou Wu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
- (2020) Wenhua Liang et al. LANCET ONCOLOGY
- Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools
- (2020) Despina Fotiou et al. Cancers
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
- (2020) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Hematological findings and complications of COVID ‐19
- (2020) Evangelos Terpos et al. AMERICAN JOURNAL OF HEMATOLOGY
- Testing for COVID-19 in lung cancer patients
- (2020) A. Passaro et al. ANNALS OF ONCOLOGY
- Managing COVID-19 in the oncology clinic and avoiding the distraction effect
- (2020) F. Cortiula et al. ANNALS OF ONCOLOGY
- Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China
- (2020) L. Zhang et al. ANNALS OF ONCOLOGY
- Care of haematology patients in a COVID‐19 epidemic
- (2020) John Willan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China
- (2020) Ruchong Chen et al. CHEST
- Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age
- (2020) Monika Engelhardt et al. HAEMATOLOGICA
- Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy
- (2020) Giacomo Grasselli et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment
- (2020) Dan M. Roden et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal
- (2020) Masumi Ueda et al. Journal of the National Comprehensive Cancer Network
- Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic
- (2020) Bruno H R de Paula et al. LANCET ONCOLOGY
- Frequently asked questions regarding SARS-CoV-2 in cancer patients—recommendations for clinicians caring for patients with malignant diseases
- (2020) Marie von Lilienfeld-Toal et al. LEUKEMIA
- Clinical Characteristics of Covid-19 in New York City
- (2020) Parag Goyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Demographic science aids in understanding the spread and fatality rates of COVID-19
- (2020) Jennifer Beam Dowd et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak
- (2020) Mengyuan Dai et al. Cancer Discovery
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
- (2020) Maria-Victoria Mateos et al. Lancet Haematology
- Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2
- (2020) Laure Elens et al. THERAPEUTIC DRUG MONITORING
- Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma
- (2020) Hira Mian et al. Journal of Geriatric Oncology
- Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations
- (2019) Corrado Girmenia et al. BLOOD REVIEWS
- The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)
- (2019) Charalampia Kyriakou et al. Blood Cancer Journal
- Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
- (2019) Hareth Nahi et al. PLoS One
- Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
- (2019) Habte Yimer et al. BRITISH JOURNAL OF HAEMATOLOGY
- Myeloma bone disease: from biology findings to treatment approaches
- (2019) Evangelos Terpos et al. BLOOD
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma
- (2019) Laura Rosiñol et al. BLOOD
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
- (2019) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple myeloma: Role of autologous transplantation
- (2019) Ioannis Ntanasis-Stathopoulos et al. CANCER TREATMENT REVIEWS
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
- (2019) Mark T Drayson et al. LANCET ONCOLOGY
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies
- (2018) Min Chen et al. ANNALS OF HEMATOLOGY
- Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: a pooled analysis
- (2018) Sara Bringhen et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Ninety-minute daratumumab infusion is safe in multiple myeloma
- (2018) Hallie Barr et al. LEUKEMIA
- Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
- (2018) Arjun Lakshman et al. Blood Cancer Journal
- Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
- (2018) Sara Bringhen et al. HAEMATOLOGICA
- Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study
- (2018) Rasmus Sørrig et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database
- (2015) Morten O. Holmström et al. AMERICAN JOURNAL OF HEMATOLOGY
- Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study
- (2015) N. Raje et al. CLINICAL CANCER RESEARCH
- European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
- (2015) E. Terpos et al. HAEMATOLOGICA
- European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
- (2015) E. Terpos et al. HAEMATOLOGICA
- Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection
- (2014) Benjamin W. Teh et al. BLOOD REVIEWS
- Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
- (2014) C. Blimark et al. HAEMATOLOGICA
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
- (2014) M A Dimopoulos et al. LEUKEMIA
- International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease
- (2013) Evangelos Terpos et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
- (2013) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide
- (2011) A. Larocca et al. BLOOD
- The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection
- (2009) M. Basler et al. JOURNAL OF IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started